{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:31:38Z","timestamp":1790746298637,"version":"4.1.0"},"reference-count":24,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T00:00:00Z","timestamp":1745107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Sodium zirconium cyclosilicate (SZC) is a novel potassium-binding agent with strong evidence supporting its efficacy in normalizing hyperkalemia. However, the long-term prognostic impact of SZC-integrated medical therapy in patients with systolic heart failure and baseline hyperkalemia remains uncertain. Methods: This study included patients with heart failure and a left ventricular ejection fraction (LVEF) of &lt;50% who were prescribed SZC for hyperkalemia between July 2020 and February 2025. Patients who continued SZC therapy for two years or until February 2025 were classified into the SZC continuation group and followed from the initiation of SZC. Those who discontinued SZC during the study period were assigned to the SZC discontinuation group, with follow-up commencing from the point of cessation. The two-year cumulative incidence of all-cause mortality or hospital readmission was compared between the groups. Results: A total of 61 patients (median age: 79 years; 33 men; median LVEF: 42%) were included in the analysis. Serum potassium levels significantly decreased in the SZC continuation group (p &lt; 0.001) but remained unchanged in the SZC discontinuation group (p = 0.23). The SZC continuation group demonstrated a trend toward a lower cumulative incidence of the primary outcome compared to the SZC discontinuation group (29% vs. 47%, p = 0.079). Additionally, in the SZC continuation group, the daily doses of renin-angiotensin system inhibitors and mineralocorticoid receptor antagonists increased significantly (p &lt; 0.05 for both). Furthermore, LVEF improved significantly with SZC-integrated medical therapy (p = 0.011), whereas no such changes were observed in the SZC discontinuation group (p &gt; 0.05 for all). Conclusions: Long-term SZC-integrated medical therapy was associated with the sustained normalization of hyperkalemia, optimization of heart failure pharmacotherapy, and improved clinical outcomes in patients with systolic heart failure and baseline hyperkalemia. These findings underscore the need for prospective randomized controlled trials in carefully selected patient populations to validate the benefits of SZC and establish its optimal supportive role in the management of systolic heart failure.<\/jats:p>","DOI":"10.3390\/jcm14082836","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T20:24:16Z","timestamp":1745180656000},"page":"2836","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Impact of Long-Term Sodium Zirconium Cyclosilicate-Integrated Medical Therapy in Patients with Systolic Heart Failure"],"prefix":"10.3390","volume":"14","author":[{"given":"Yuki","family":"Hida","sequence":"first","affiliation":[{"name":"Second Department of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-7637","authenticated-orcid":false,"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[{"name":"Second Department of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Second Department of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40265-018-0991-6","article-title":"Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Stavros, F., Yang, A., Leon, A., Nuttall, M., and Rasmussen, H.S. (2014). Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0114686"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/14656566.2020.1810234","article-title":"An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia","volume":"22","author":"Takkar","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_4","first-page":"54","article-title":"Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: The randomized, placebo-controlled HARMONIZE-Global study","volume":"7","author":"Zannad","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2019050450","article-title":"A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia","volume":"30","author":"Fishbane","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study","volume":"14","author":"Spinowitz","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s10157-020-01972-y","article-title":"A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia","volume":"25","author":"Kashihara","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ndt\/gfz285","article-title":"Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: Comparative results from an open-label, Phase 3 study","volume":"36","author":"Roger","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1159\/000504078","article-title":"Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE","volume":"50","author":"Roger","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"sfae083","DOI":"10.1093\/ckj\/sfae083","article-title":"Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: A multicountry cohort study","volume":"17","author":"Rastogi","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Pollack, C.V., Arroyo, D., Kanda, E., Lazaro, I.J.S., Lesen, E., Franzen, S., Gray, C.M., Lipinska, A., Murohara, T., and Rastogi, A. (2024). Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode. ESC Heart Fail.","DOI":"10.1002\/ehf2.15171"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","article-title":"Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure","volume":"85","author":"Kosiborod","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","article-title":"JCS\/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"27","author":"Tsutsui","year":"2021","journal-title":"J. Card. Fail."},{"key":"ref_14","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am. J. Manag. Care."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e012655","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom","volume":"8","author":"Linde","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ekir.2019.05.018","article-title":"Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan","volume":"4","author":"Kashihara","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., and Izumi, C. (2025). JCS\/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure. J. Card. Fail.","DOI":"10.1016\/j.cardfail.2025.02.014"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e13941","DOI":"10.1111\/ijcp.13941","article-title":"Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions","volume":"75","author":"Tafesse","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.jchf.2024.08.007","article-title":"Mineralocorticoid Antagonism in Heart Failure: Established and Emerging Therapeutic Role","volume":"12","author":"Chang","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Imamura, T., Narang, N., Onoda, H., Tanaka, S., Ushijima, R., Sobajima, M., Fukuda, N., Ueno, H., and Kinugawa, K. (2023). Negative Prognostic Impact of Mineralocorticoid Receptor Antagonist in Elderly Patients Receiving TAVR. J. Clin. Med., 12.","DOI":"10.3390\/jcm12113742"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kida, K., Horiuchi, Y.U., Sato, S., Kitai, T., Okumura, T., Imamura, T., Sakamoto, T., Matsue, Y., and REGISTA-K Trial Investigators (2024). Efficacy and Safety of Sodium Zirconium Cyclosilicate in the Management of Hyperkalemia in Patients with Heart Failure with Reduced and Mildly Reduced Ejection Fraction and Chronic Kidney Disease Treated with Spironolactone: Rationale for and Design of the REGISTA-K Trial. J. Card. Fail.","DOI":"10.1016\/j.cardfail.2024.11.017"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Baran, W., Krzeminska, J., Szlagor, M., Wronka, M., Mlynarska, E., Franczyk, B., and Rysz, J. (2021). Mineralocorticoid Receptor Antagonists-Use in Chronic Kidney Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189995"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2836\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:18:10Z","timestamp":1760030290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,20]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14082836"],"URL":"https:\/\/doi.org\/10.3390\/jcm14082836","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,20]]}}}